Using artificial intelligence to improve breast cancer screening in Norway
Artificial Intelligence in BreastScreen Norway - a Randomized Controlled Trial
This study is testing if using artificial intelligence to help read mammograms can find breast cancer just as well as the usual method done by radiologists.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 150000 (estimated) |
| Ages | 50 Years to 69 Years |
| Sex | Female |
| Sponsor | Norwegian Institute of Public Health Government |
| Locations | 1 site (Oslo) |
| Trial ID | NCT06032390 on ClinicalTrials.gov |
What this trial studies
This randomized controlled trial aims to compare breast cancer detection rates among women whose mammograms are interpreted using artificial intelligence (AI) alongside one or two radiologists versus those interpreted through standard double reading. The study addresses the challenges of missed cancers in traditional screening methods and the shortage of breast radiologists. Participants will be randomly assigned to either the AI-assisted interpretation group or the control group, with all examinations analyzed by AI to determine the risk of malignancy. The goal is to demonstrate that AI-assisted interpretation is at least as effective as the standard procedure.
Who should consider this trial
Good fit: Ideal candidates are women participating in the BreastScreen Norway mammography program who provide informed consent.
Not a fit: Patients who do not provide informed consent or are not part of the BreastScreen Norway program will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enhance breast cancer detection rates and streamline the screening process.
How similar studies have performed: Retrospective studies have shown promising results for AI in mammography, but this is a prospective trial that will provide new insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women attending the population-based mammography screening program BreastScreen Norway providing a signed, informed consent Exclusion Criteria: * Women attending the population-based mammography screening program BreastScreen Norway not providing a signed, informed consent
Where this trial is running
Oslo
- Cancer Registry of Norway, Norwegian Institute of Public Health — Oslo, Norway (Recruiting)
Study contacts
- Principal investigator: Solveig Hofvind, PhD — Norwegian Institute of Public Health
- Study coordinator: Solveig Hofvind, PhD
- Email: sshh@kreftregisteret.no
- Phone: 22928828
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.